Loading…
Sickle Cell Disease Comprehensive Care Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,649 other S bills in the 118th — cohort avg 33d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2024 · fourth_quarter · Health Issues
Medicaid program reforms, including telemedicine and prior authorization issues Section 340B Drug Pricing program, including H.R. 5378 (Lower Costs, More Transparency Act), Section 202 Drug pricing reforms generally Juvenile mental and behavioral health legislation generally "Food as medicine" nutrition programs generally H.R. 3884 and S. 1852 (Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023), all provisions H.R. 3391 (Gabriella Miller Kids First Research Act 2.0), all provisions H.R. 3887 (Childrens Hospital GME Support Reauthorization Act of 2023), all provisions Medicare "site neutral" payment policy generally, including H.R. 5378 (Lower Costs, More Transparency Act), Section 203 Pediatric cancer research generally Pediatric access to cell and gene therapies generally H.R. 4758 (Accelerating Kids Access to Care Act), all provisions H.R. 7213 (Autism Collaboration, Accountability, Research, Education, and Support Act of 2024), all provisions H.R. 8260 and S. 4350 (Hospital Inpatient Services Modernization Act), all provisions H.R. 10545 (American Relief Act, 2025), regarding HHS program funding and Medicaid program reform provisions National Institutes of Health program reforms generally S. 904 (Sickle Cell Disease Comprehensive Care Act), all provisions Note: Elizabeth Horner, a lobbyist for the listed client, did not lobby, and did not make any communication to, appearance before, or lobbying contact with, the Senate, any Senator or any officer or employee of the Senate, on behalf of the listed client.
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Health Issues
Medicaid program reforms, including telemedicine and prior authorization issues Section 340B Drug Pricing program, including H.R. 5378 (Lower Costs, More Transparency Act), Section 202 Drug pricing reforms generally Juvenile mental and behavioral health legislation generally "Food as medicine" nutrition programs generally H.R. 3884 and S. 1852 (Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023), all provisions H.R. 3391 (Gabriella Miller Kids First Research Act 2.0), all provisions H.R. 3887 (Childrens Hospital GME Support Reauthorization Act of 2023), all provisions Medicare "site neutral" payment policy generally, including H.R. 5378 (Lower Costs, More Transparency Act), Section 203 Pediatric cancer research generally Pediatric access to cell and gene therapies generally H.R. 4758 (Accelerating Kids Access to Care Act), all provisions H.R. 7213 (Autism Collaboration, Accountability, Research, Education, and Support Act of 2024), all provisions H.R. 8260 and S. 4350 (Hospital Inpatient Services Modernization Act), all provisions H.R. 10545 (American Relief Act, 2025), regarding HHS program funding and Medicaid program reform provisions National Institutes of Health program reforms generally S. 904 (Sickle Cell Disease Comprehensive Care Act), all provisions
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Health Issues
Medicaid program reforms, including telemedicine and prior authorization issues Section 340B Drug Pricing program, including H.R. 5378 (Lower Costs, More Transparency Act), Section 202 Drug pricing reforms generally Juvenile mental and behavioral health legislation generally "Food as medicine" nutrition programs generally H.R. 3884 and S. 1852 (Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023), all provisions H.R. 3391 (Gabriella Miller Kids First Research Act 2.0), all provisions H.R. 3887 (Children's Hospital GME Support Reauthorization Act of2023), all provisions Medicare "site neutral" payment policy generally, including H.R. 5378 (Lower Costs, More Transparency Act), Section 203 Pediatric cancer research generally Pediatric access to cell and gene therapies generally H.R. 4758 (Accelerating Kids' Access to Care Act), all provisions H.R. 7213 (Autism Collaboration, Accountability, Research, Education, and Support Act of2024), all provisions H.R. 8260 and S. 4350 (Hospital Inpatient Services Modernization Act), all provisions H.R. I 0545 (American Relief Act, 2025), regarding HHS program funding and Medicaid program reform provisions National Institutes of Health program reforms generally S. 904 (Sickle Cell Disease Comprehensive Care Act), all provisions
Client expense: $190,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE